Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement

Mistry Khushboo, Kavya Naik, Vasanthi, Alicia Menezes, Anup Naha, K. B. Koteshwara, K. Girish Pai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)

Original languageEnglish
Pages (from-to)3043-3048
Number of pages6
JournalResearch Journal of Pharmacy and Technology
Volume10
Issue number9
DOIs
Publication statusPublished - 01-09-2017

Fingerprint

irbesartan
Sonication
Excipients
Pharmaceutical Preparations
Buffers
Angiotensin Receptor Antagonists
Fourier Transform Infrared Spectroscopy
Drug Interactions
Particle Size
Surface-Active Agents
Nanoparticles
Solubility
Biological Availability
Software
Phosphates
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Pharmacology (medical)

Cite this

@article{2c9c1d0e97774ac2becea30cc2c6b72d,
title = "Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement",
abstract = "Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09{\%}) as compared to pure drug dispersion (67.69{\%})",
author = "Mistry Khushboo and Kavya Naik and Vasanthi and Alicia Menezes and Anup Naha and Koteshwara, {K. B.} and {Girish Pai}, K.",
year = "2017",
month = "9",
day = "1",
doi = "10.5958/0974-360X.2017.00540.6",
language = "English",
volume = "10",
pages = "3043--3048",
journal = "Research Journal of Pharmacy and Technology",
issn = "0974-3618",
publisher = "A and V Publication",
number = "9",

}

Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement. / Khushboo, Mistry; Naik, Kavya; Vasanthi; Menezes, Alicia; Naha, Anup; Koteshwara, K. B.; Girish Pai, K.

In: Research Journal of Pharmacy and Technology, Vol. 10, No. 9, 01.09.2017, p. 3043-3048.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement

AU - Khushboo, Mistry

AU - Naik, Kavya

AU - Vasanthi,

AU - Menezes, Alicia

AU - Naha, Anup

AU - Koteshwara, K. B.

AU - Girish Pai, K.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)

AB - Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (-5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)

UR - http://www.scopus.com/inward/record.url?scp=85040769711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040769711&partnerID=8YFLogxK

U2 - 10.5958/0974-360X.2017.00540.6

DO - 10.5958/0974-360X.2017.00540.6

M3 - Article

AN - SCOPUS:85040769711

VL - 10

SP - 3043

EP - 3048

JO - Research Journal of Pharmacy and Technology

JF - Research Journal of Pharmacy and Technology

SN - 0974-3618

IS - 9

ER -